



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/628,387	08/01/2000	Patrick Soon-Shiong	ABII1150-18	5713

7590 02/10/2003

STEPHEN E. REITER  
FOLEY & LARDNER  
P. O. BOX 80278  
SAN DIEGO, CA 92138-0278

[REDACTED] EXAMINER

PULLIAM, AMY E

ART UNIT	PAPER NUMBER
1615	16

DATE MAILED: 02/10/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/628,387	SOON-SHIONG ET AL.
	Examiner Amy E Pulliam	Art Unit 1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 20 September 2002.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-16,30-44,58-78,98-101,104-107,110-113,116-119,122-125,128-131,133-135,137-141,145-147,149-151,153-158,160-162 and 164-188 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
 If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
 \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
 a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                             | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

U.S. Patent and Trademark Office  
PTO-326 (Rev. 04-01)

**Office Action Summary**

Part of Paper No. 16

Continuation of Disposition of Claims: Claims pending in the application are 1-16,30-44,58-78,98-101,104-107,110-113,116-119,122-125,128-131,133-135,137-141,145-147,149-151,153-158,160-162 and 164-188.

## DETAILED ACTION

### *Receipt of Papers*

Receipt is acknowledged of the Request for Extension of Time and the Request for Reconsideration, both received by the Office on September 20, 2002.

### *Double Patenting*

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-16, 30-44, 58-78, 98-101, 104-107, 110-113, 116-119, 122-125, 128-131, 133-135, 137-141, 145-147, 149-151, 153-158, 160-162, 164-177 remain rejected under the judicially created doctrine of double patenting over claims 1-57 of U. S. Patent No. 6,096,331 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent.

The subject matter claimed in the instant application is fully disclosed in the patent and is covered by the patent since the patent and the application are claiming common subject matter, as follows: a unit dosage form comprising a taxane for systemic administration.

Claims 1-16, 30-44, 58-78, 98-101, 104-107, 110-113, 116-119, 122, 125, 128-131, 133-135, 137-141, 145-147, 149-151, 153-158, 160-162, 164-166, 168, and 170 remain provisionally rejected under the judicially created doctrine of double patenting over claims 1-78 of copending Application No. 09/628,389. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows: a unit dosage form comprising a taxane for systemic administration.

Applicant has acknowledged the rejection, and has agreed to address it if the claims are found allowable. However, at this time, this rejection maintained.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-16, 30-44, 58-78, 98-101, 104-107, 110-113, 116-119, 122-125, 128-131, 133-135, 137-141, 145-147, 149-151, 153-158, 160-162, 164-177 are rejected under 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. Elements which are critical or essential to the practice of the invention, but not included in the claim(s) are not enabled by the disclosure. See *In re Mayhew*, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976).

At page 11 of the instant specification, applicant teaches “in accordance with the present invention, there are provided compositions and methods useful for in vivo delivery of biologics, in the form of nanoparticles that are suitable for parenteral administration in aqueous suspension. [The] invention compositions comprise drugs, such as paclitaxel, stabilized by a polymer. The polymer is a biocompatible material, such as the protein albumin.” Applicant has defined their invention in this paragraph broadly to include nanoparticles of the specific drug, stabilized by a polymer, and suspended in an aqueous solution for parenteral administration, however, none of these defining elements are found in the claim. Additionally, at page 12, 112-13, applicant states that it is very surprising that the invention formulation of paclitaxel, Capxol, a nanoparticle formulation, concentrates in tissues. Further, at lines 24-30 states that the basis for the unexpected results (localization within the prostate) could be a result of the specific particle size of the formulation (20-400 nm), or the presence of the protein albumin in the formulation. Again, it appears that the unexpected results of applicant’s claimed invention are at least in part due to the formulation being nanoparticles, and the formulation comprising albumin, however, neither of these limitations are recited in the claims. Based on the disclosures in the specification, applicant’s invention appears to be a composition known as Capxol<sup>TM</sup>, which is a lyophilized powder, with a particular particle size range, containing paclitaxel and human serum albumin. Applicant has omitted essential elements from the claims, and appropriate correction is required.

Applicant’s arguments have been fully considered, but are not found to be persuasive.

Applicant argues that the invention set forth in claim 1 is drawn to an article of manufacture

Art. Unit: 1615

which comprises a sealed vial with a specified amount of taxane in the vial. Applicant argues, therefore, that all the elements which are critical or essential to the practice of the invention. The examiner respectfully disagrees. As discussed above, the instant specification refers to a formulation of taxane, or paclitaxel, but it species other necessary ingredients in the formulation. As applicant has included none of these other limitations in the claim, the examiner maintains her rejection.

#### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 1-14, 16, 30-42, 44, 58-76, 78, 98, 99, 101, 104, 105, 107, 110, 111, 113, 116, 117, 119, 122, 123, 125, 128, 129, 131, 133, 135, 137-139, 141, 145, 147, 149, 151, 153-154, 156, 158, 160, 162, 164-168, 170, and 172-177 are rejected under 35 U.S.C. 102(b) as being unpatentable over pages 2780-2785 of the 1994 edition of Drug Facts and Comparisons.

Drugs, Facts and Comparisons teaches that on December 29, 1992, the FDA approved paclitaxel for treatment. Further, the reference shows that the formulations which were approved are 135 mg/m<sup>2</sup> or 175 mg/m<sup>2</sup>, administered intravenously over three hours every three weeks. This disclosure alone suggests applicants claimed formulations and methods.

However, applicant has amended the claims to include the unit dosage form in a sealed vial. The examiner points to the bottom of page 2785, which shows that paclitaxel is stored in single dose vials. This disclosure anticipates the new limitation to applicant's claims.

Applicant's arguments have been fully considered but are not found to be persuasive. Applicant argues that those skilled in the art readily recognize that unit dosage forms comprising taxane in the range contemplated by the present claims were not available as of December 1992. Applicant further argues that the amounts taught by the reference do not anticipate the instant claims. Neither of these arguments is found persuasive. Applicant has claimed a composition, not in terms of how much active agent will be in the vial, but in terms of how much active agent will be given to the patient. This will greatly depend on who the formulation is being administered to, a child? An adult? An animal? Therefore, this line of arguments is not found persuasive. The examiner's line of reasoning might be overcome if the claims specified a particular amount of active, or a particular patient for the administration.

Additionally, applicant argues that the formulation in the reference is administered over 24 hours, while applicant claims administration over 3 hours. This argument is found unpersuasive, because the time of administration is a limitation regarding the future intended use of the composition. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re*

Art Unit: 1615

*Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

To reiterate the examiner's previous assertions, Applicant argues that the reference does not teach unit dosage forms, or describe single doses containing taxane in the range of about 30mg/m<sup>2</sup> to about 1000 mg/m<sup>2</sup>. The examiner respectfully disagrees. The reference clearly teaches a single dosage of a taxane, in the amount of 135 mg/m<sup>2</sup> or 175 mg/m<sup>2</sup>, to be administered over a three hour period. Applicant is asserting that there is a blatant difference between this reference and a unit dosage form, but it is the position of the examiner that the teaching of the reference *is* a unit dosage form, specifically in light of the teaching at the bottom of page 2785, which states paclitaxel is stored in single dose vials. Furthermore, it is the position of the examiner that a teaching to a single dosage form is the equivalent of a teaching to the recommended quantity of drug to be administered to a subject. In both instances, the teaching would disclose the specific amount of drug to be included in a formulation, which would be administered to a patient at one sitting.

Therefore, this rejection is maintained, and made final.

Claims 1-15, 30-43, 58-77, 98-100, 104-106, 110-112, 116-118, 122-124, 128-130, 133-134, 137-140, 145-146, 149-150, 153-157, 160-161, 164-171, and 177 are rejected under 35 U.S.C. 102(b) as being anticipated by page 3558 of Drug Facts and Comparisons. This reference teaches that on May 14, 1996 the FDA approved docetaxel for treatment. Further, the reference shows that the formulations which were approved are 60 mg/m<sup>2</sup> to 100 mg/m<sup>2</sup>, administered intravenously over an hour every three weeks. This disclosure directly anticipates applicants claimed formulations and methods.

Art Unit: 1615

However, applicant has amended the claims to include the unit dosage form in a sealed vial. The examiner points to the bottom of page 3558, which shows that docetaxel is stored in single dose vials. This disclosure anticipates the new limitation to applicant's claims.

Applicant's arguments have been fully considered but are not found to be persuasive for the reasons stated above. This rejection is maintained, and made final.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-16, 30-44, 58-78, 98-101, 104-107, 110-113, 116-119, 122-125, 128-131, 133-135, 137-141, 145-147, 149-151, 153-158, 160-162, and 164-177 are rejected under 35 U.S.C. 103(a) as being unpatentable over pages 2780-2785 or page 3558 of Drug Facts and Comparisons as applied above. The reference does not specifically state the mg amounts as claimed by applicant in claims 58 –78. However, the reference does teach the same concentration amounts, thereby implying that the dosages contain the same amounts, especially as they are used for the same purpose, over the same period of time. One of ordinary skill in the art would have been motivated to make a pharmaceutical formulation of a taxane, either paclitaxel or docetaxel, based on the disclosure in Drug Facts and Comparisons, as the

Art Unit: 1615

formulations claimed by applicant are taught in the reference for each of these drugs. The expected result would be a successful antitumor formulation. Therefore, this invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Applicant's arguments have been fully considered but are not found to be persuasive for the reasons stated above. This rejection is maintained, and made final.

### ***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E Pulliam whose telephone number is 703-308-4710. The examiner can normally be reached on Mon-Thurs 7:30-5:00, Alternate Fri 8:30-5:00.

Art-Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

A. Pulliam  
Patent Examiner/ AU 1615  
February 3, 2003

  
THURMAN R. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600